Cancer

August 6, 2017

The Ptpn2 pathway blockade enhances the efficacy of Cancer immunotherapy: Ivermectin, the anti-parasitic drug, inhibits the expression of protein tyrosine phosphatase PTPN2, increases interferon-IFNγ signalling, augments antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 6/August/2017, 11.01 pm

Introduction:What they say: A recent study from Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA; Broad Institute of Harvard and Massachusetts Institute of […]
August 6, 2017

Natural product-derived therapy for EVI-1-Overexpressing Acute Myeloid Leukemia: Sulforaphane, isolated from Broccoli, decreases the expression of MECOM/EVI-1 and its down target genes, including CKMT-1, alters Arginine-creatine metabolism, inhibits mitochondrial respiration, depletes ATP levels, and promotes regression of EVI-1-overexpressing AML via up regulation of its target gene, 6/August/2017, 10.52 pm

Introduction: What they say: A study from the Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA; […]
August 6, 2017

Natural product therapy for KRAS/LKB1-mutant lung cancer: Ivermecitin increases the levels of tumor suppressor proteins, inhibits the expression of urea cycle enzyme carbamoyl phosphate synthetase-1 (CSP1), decreases pyrimidine pools, stalls DNA synthesis, and inhibits the progression of KRAS/LKB1-mutated lung cancers via up regulation of its target gene, 6/August/2017, 10.29 pm

Introduction: What they say A study from the Children’s Medical Center Research Institute, UT Southwestern Medical Center, Dallas, Texas 75390, USA; Department of Pediatrics, UT Southwestern Medical Center, […]
August 5, 2017

Molecular therapy for prostate cancer bone metastasis: Ivermectin inhibits the expression of Monoamine oxidase A (MAOA), inhibits Shh-IL6-RANKL signaling network, suppresses tumor-stromal interactions, reduces prostate cancer metastasis and prolongs survival via up regulation of its target gene, 5/August/2017, 11.26 pm

Introduction: What they say: A study from the Uro-Oncology Research Program, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA shows that “MAOA-Dependent Activation of Shh-IL6-RANKL Signaling Network […]